Iran unveils four new pharmaceutical drugs to fight cancer and diabetes

Iran press/Iran news: The new drugs unveiled on Tuesday morning were cancer-fighting drugs, including Sorafenib, a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), and advanced primary liver cancer (hepatocellular carcinoma).

Another cancer-fighting drug unveiled was Regorafenib, an oral multi-kinase inhibitor that is used in the therapy of colorectal cancer, hepatocellular carcinoma and gastrointestinal cancer.

Two anti-diabetes drugs were also unveiled on Tuesday morning, namely Empagliflozin, a medication used together with diet and exercise for treatment of type 2 diabetes, and Dapagliflozin, another medication used to treat type 2 diabetes. 

It is estimated that a one-billion-dollar market for anti-cancer drugs exists within the Islamic Republic of Iran. Production of these four new pharmaceutical drugs will further strengthen the reputation of Iran as having an advanced and competitive pharmaceutical industry. 211/103

Read more:

Pharmaceutical industry supplying $700m of Iran’s needed foreign currency

Shortage of pharmaceutical drugs only affects two percent of medicines